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Multivariable Analysis of Outcome Predictors and
Adjustment of Main Outcome Results to Baseline Data
Profile in Randomized Controlled Trials
Safe Implementation of Thrombolysis in Stroke-MOnitoring
STudy (SITS-MOST)
Nils Wahlgren, MD, PhD; Niaz Ahmed, MD, PhD; Niclas Eriksson, MSc; Franz Aichner, MD;
Erich Bluhmki, PhD; Antoni Da´valos, MD, PhD; Terttu Erila¨, MD, PhD; Gary A. Ford, FRCP;
Martin Grond, MD; Werner Hacke, MD, PhD; Michael G. Hennerici, MD, PhD;
Markku Kaste, MD, PhD, FAHA, FESC; Martin Ko¨hrmann, MD; Vincent Larrue, MD;
Kennedy R. Lees, MD, FRCP; Thomas Machnig, MD, MBA; Risto O. Roine, MD, PhD;
Danilo Toni, MD, PhD; Geert Vanhooren, MD; for the SITS-MOST Investigators
Background and Purpose—The Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST)
unadjusted results demonstrated that intravenous alteplase is well tolerated and that the effects were comparable with
those seen in randomized, controlled trials (RCTs) when used in routine clinical practice within 3 hours of ischemic
stroke onset. We aimed to identify outcome predictors and adjust the outcomes of the SITS-MOST to the baseline
characteristics of RCTs.
Methods—The study population was SITS-MOST (n6483) and pooled RCTs (n464) patients treated with intravenous
alteplase within 3 hours of stroke onset. Multivariable, backward stepwise regression analyses (until P0.10) were
performed to identify the outcome predictors for SITS-MOST. Variables appearing either in the final multivariable
model or differing (P0.10) between SITS-MOST and RCTs were included in the prediction model for the adjustment
of outcomes. Main outcome measures were symptomatic intracerebral hemorrhage, defined as National Institutes of
Health Stroke Scale deterioration1 within 7 days with any hemorrhage (RCT definition), mortality, and independency
as defined by modified Rankin Score of 0 to 2 at 3 months.
Results—The adjusted proportion of symptomatic intracerebral hemorrhage for SITS-MOST was 8.5% (95% CI, 7.9 to 9.0)
versus 8.6% (6.3 to 11.6) for pooled RCTs; mortality was 15.5% (14.7 to 16.2) versus 17.3% (14.1 to 21.1); and independency
was 50.4% (49.6 to 51.2) versus 50.1% (44.5 to 54.7), respectively. In the multivariable analysis, older age, high blood
glucose, high National Institutes of Health Stroke Scale score, and current infarction on imaging scans were related to poor
outcome in all parameters. Systolic blood pressure, atrial fibrillation, and weight were additional predictors of symptomatic
intracerebral hemorrhage. Current smokers had a lower rate of symptomatic intracerebral hemorrhage. Disability before
current stroke (modified Rankin Score 2 to 5), diastolic blood pressure, antiplatelet other than aspirin, congestive heart failure,
patients treated in new centers, and male sex were related to high mortality at 3 months.
Conclusions—The adjusted outcomes from SITS-MOST were almost identical to those in relevant RCTs and reinforce the
conclusion drawn previously in the unadjusted analysis. We identified several important outcome predictors to better
identify patients suitable for thrombolysis. (Stroke. 2008;39:3316-3322.)
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One of the preconditions laid down for the EuropeanUnion license provided in 2002 for the use of intrave-
nous alteplase in the treatment of acute ischemic stroke
within 3 hours of symptom onset was that the Safe Imple-
mentation of Thrombolysis in Stroke-MOnitoring STudy
(SITS-MOST) be performed. Another condition was that a
randomized, placebo-controlled study be undertaken to assess
the use of alteplase in patients with stroke within the extended
therapeutic window of between 3 and 4.5 hours (European
Cooperative Acute Stroke Study [ECASS] III).
SITS-MOST has demonstrated that intravenous alteplase is
well tolerated and that when used in routine clinical practice
(administered to suitable patients within 3 hours of the onset
of acute ischemic stroke), the effects were comparable with
those seen in the randomized, controlled trials (RCTs).1 The
conclusions were based on a comparison of the results from
SITS-MOST with those from the active arms of relevant
pooled, RCTs.2 The results suggested a trend toward a more
favorable outcome in SITS-MOST compared with RCTs. For
mortality, the difference in favor of SITS-MOST was robust.
However, the results also showed differences for several
baseline variables between the 2 study populations. This
prompted the current multivariable analysis to evaluate the
prognostic potential of these variables and adjust the SITS-
MOST main outcome results for these prognostically impor-
tant variables.
In this article, multivariable models were used to identify
the prognostically important baseline factors for the main
outcomes in SITS-MOST as a basis for adjustment of the
main outcomes compared with a case-mix from RCTs.
Methods
Patients and Procedures
The methodology for SITS-MOST and the SITS International Stroke
Thrombolysis Register (SITS-ISTR), including the structure of the
SITS network, procedure for data collection and management,
patient identification, and verification of source data, have been
described previously.1 In brief, SITS-MOST was a prospective,
open, multinational, observational monitoring study for clinical
centers using thrombolysis for the treatment of acute stroke within
countries affiliated to the European Evaluation of Medicines Agency
(EMEA). The study period was between December 2002 and April
2006. The study was established as a cohort of SITS-ISTR, an
Internet-based, academic-driven, interactive thrombolysis register.3
Baseline and demographic characteristics, stroke severity (as
measured by National Institutes of Health Stroke Scale [NIHSS]
score), time intervals, risk factors, medication history, and imaging
scan data taken on admission were collected. Outcome measure-
ments were NIHSS score at 2 hours, 24 hours, and 7 days; imaging
scan data after treatment; and modified Rankin Score (mRS) at 3
months.
A center’s previous experience with stroke thrombolysis was
designated as “experienced” if they had participated in one or both of
the ECASS studies and/or had performed at least 5 thrombolytic
procedures in patients with stroke before entering SITS-MOST.
Centers that lacked such experience were designated “new.”
Main Outcome Measurements
The main outcome measurements from SITS-MOST were symptom-
atic intracerebral hemorrhage (SICH), mortality, and functional
independence. These measurements were defined as follows: (1)
SICH per the RCT definition: symptomatic (any deterioration in
NIHSS score within 7 days) intracerebral hemorrhage of any type in
any posttreatment imaging scans after the start of thrombolysis
treatment.2 This definition was used for the current study to enable
comparisons with RCTs; (2) death within 3 months (mRS 6); (3) rate
of independency (mRS 0 to 2) at 3 months; and (4) SICH per the
SITS-MOST definition: symptomatic (deterioration in NIHSS score of
4 points within 24 hours) intracerebral hemorrhage type 2 in the 22 to
36 hours follow-up imaging scans after the start of thrombolysis
treatment. SICH per the SITS-MOST definition results were available
for only the first part of the analysis, because the comparison of data
from pooled RCT with this definition is not available.
Statistical Methods
First Analysis
Descriptive statistics for the baseline and demographic data from
SITS-MOST were presented according to the main outcomes: SICH
per SITS-MOST definition, SICH per RCT definition, mortality, and
rate of independence at 3 months (Table 1). Unknown values were
excluded from the denominator when calculating proportions as done
in the previous publication.1
Multivariable logistic regression analyses were performed in an
explorative manner to find predictors for the main outcomes. These
analyses were based on the baseline and demographic data from
SITS-MOST. Variables not showing a linear relationship to an
outcome on the logit scale were categorized according to clinical
relevance. To avoid variable selection caused by spurious correla-
tions, only variables showing a relationship to the outcome (defined
as univariable P0.25) were included as potential predictors. No
interaction terms were included in the models. For each main
outcome, a backward stepwise procedure was performed using
P0.10 of the likelihood ratio test for exclusion. The variables
included for each respective outcome were (1) common in all
analyses—age, antiplatelet other than aspirin, aspirin, atrial fibrilla-
tion, glucose, hypertension, and signs of current infarction at
baseline imaging; (2) SICH per SITS-MOST definition—alteplase
dose (milligrams/kilograms body weight), diabetes, NIHSS baseline
categories, previous stroke, systolic blood pressure, and weight; (3)
SICH per RCT definition—alteplase dose (milligrams/kilograms
body weight), antihypertensive treatment, diabetes, hyperlipidemia,
NIHSS baseline categories, smoking, systolic blood pressure, and
weight; (4) mortality—alteplase dose (milligrams/kilograms body
weight), centers’ previous stroke experience, congestive heart fail-
ure, diabetes, diastolic blood pressure categories, sex, hyperlipid-
emia, NIHSS baseline, previous stroke, rate of normal function
(mRS 0 to 1) before stroke, and systolic blood pressure; and (5)
independence—antihypertensive treatment, congestive heart failure,
diabetes, diastolic blood pressure categories, sex, NIHSS at baseline,
previous stroke, rate of normal function (mRS 0 to 1) before stroke,
systolic blood pressure categories, and weight.
Second Analysis
For the second analysis, a prediction model was built with a similar
approach as it was performed in the first multivariable analysis of the
SITS-MOST data but repeated only with the variables occurring in
both SITS-MOST and RCTs. Variables appearing in the final model
of the first multivariable analysis and variables not appearing in the
final model but differing significantly (defined as P0.10) between
SITS-MOST and pooled RCTs were added into the prediction
model. Baseline data from NINDS A (n143),4 NINDS B (n168),4
ECASS I (n49),5 ECASS II (n81),6 and ATLANTIS A, B
(n23)7,8 for patients treated with alteplase within 3 hours of stroke
symptom onset were extracted and pooled for the RCT case-mix.
The SITS-MOST outcomes were then predicted using the baseline
data from the relevant pooled RCTs.
Variables included in each prediction model were as follows: (1)
common in all analyses—age, aspirin, congestive heart failure,
diabetes, glucose, previous stroke, time from stroke onset to treat-
ment, and weight; (2) SICH per SITS-MOST definition—diastolic
blood pressure, NIHSS baseline categories, and systolic blood
pressure; (3) SICH per RCT definition—atrial fibrillation, diastolic
blood pressure, NIHSS baseline categories, and systolic blood
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pressure; (4) mortality—diastolic blood pressure categories, sex,
NIHSS at baseline, and systolic blood pressure; and (5) indepen-
dence—diastolic blood pressure categories, hypertension, NIHSS at
baseline, and systolic blood pressure categories.
In the second analysis, the performance of each model on
SITS-MOST data was assessed by the c statistic (area under the
receiver operating characteristic curve).9 The c statistic of 0.5 means
that the model is inadequate and might as well have occurred by
chance and 1.0 equals perfect prediction. Because prediction models
tend to be overoptimistic when evaluated on the same data (ie,
SITS-MOST data), crossvalidation procedures were performed on
SITS-MOST to achieve unbiased estimates of the c statistic. The
uncertainty of the prediction of the RCT data and the c statistic was
therefore evaluated by randomly selecting 70% of the observations
as training data and the rest as validation data. This was repeated
10 000 times; for each run, the prediction model based on the
training data was used to calculate the c statistic on the validation
data and to predict the result using RCT data. The mean and 2.5 of
97.5 percentiles of the resulting distributions of the c statistic and
prediction results were calculated.
To calculate the 95% CIs of the observed proportions for SICH,
mortality, and rate of independence in the SITS-MOST and RCT mix
population, a score method with continuity correction10 was used.
For statistical analyses, R version 2.5.1 (R foundation for statis-
tical computing, Vienna, Austria) and SAS version 9.1.3 (SAS
Institute Inc, Cary, NC) were used.
Table 1. Baseline Characteristics of Patients According to the Main Outcome Variables*
Baseline
Characteristic
Main Outcome Variable
SICH/SITS-MOST Definition SICH/RCT Definition Dead at 3 Months Independent (mRS 0–2) at 3 Months
No (n6337) Yes (n107) P Value No (n5970) Yes (n468) P Value No (n5517) Yes (n701) P Value No (n2774) Yes (n3362) P Value
Median age, years 68 73 0.001 68 71 0.001 68 72 0.001 70 66 0.001
Sex, no. of women 2522/6337 (40) 45/107 (42) 0.64 2372/5970 (40) 189/468 (40) 0.78 2210/5517 (40) 265/701 (38) 0.25 1157/2774 (42) 1291/3362 (38) 0.008
mRS 0–1 before
stroke
5768/6197 (93) 99/104 (95) 0.40 5443/5841 (93) 418/452 (92) 0.57 5063/5408 (94) 598/675 (89) 0.001 2461/2703 (91) 3128/3299 (95) 0.001
Hypertension 3611/6179 (58) 78/103 (76) 0.001 3369/5822 (58) 314/454 (69) 0.001 3088/5385 (57) 463/681 (68) 0.001 1718/2701 (64) 1790/3287 (54) 0.001
Diabetes mellitus 991/6234 (16) 23/102 (23) 0.07 896/5875 (15) 117/455 (26) 0.001 796/5433 (15) 165/684 (24) 0.001 536/2719 (20) 410/3317 (12) 0.001
Hyperlipidemia 1920/5538 (35) 38/91 (42) 0.16 1792/5220 (34) 166/406 (41) 0.008 1654/4827 (34) 229/601 (38) 0.062 850/2413 (35) 1005/2942 (34) 0.415
Atrial fibrillation 1455/6164 (24) 38/105 (36) 0.003 1333/5811 (23) 161/452 (36) 0.001 1207/5369 (22) 236/682 (35) 0.001 757/2712 (28) 673/3261 (21) 0.001
Congestive heart
failure
461/6200 (7) 9/103 (9) 0.62 428/5844 (7) 39/453 (9) 0.31 379/5412 (7) 85/679 (13) 0.001 254/2711 (9) 203/3302 (6) 0.001
Previous stroke 618/6254 (10) 20/104 (19) 0.002 585/5894 (10) 52/456 (11) 0.31 527/5455 (10) 94/683 (14) 0.001 304/2727 (11) 308/3331 (9) 0.01
Smoking
Nonsmoker 2897/5489 (53) 52/88 (59) 0.50 2712/5196 (52) 234/377 (62) 0.001 2554/4851 (53) 285/541 (53) 0.003 1268/2314 (55) 1529/3012 (51) 0.002
Current smoker 1447/5489 (26) 20/88 (23) 1399/5196 (27) 66/377 (17.5) 1301/4851 (27) 116/541 (21) 553/2314 (24) 847/3012 (28)
Previous smoker 1145/5489 (21) 16/88 (18) 1085/5196 (21) 77/377 (20) 996/4851 (20) 140/541 (26) 493/2314 (21) 636/3012 (21)
Aspirin at stroke
onset
1853/6297 (29) 49/106 (46) 0.001 1733/5933 (29) 170/464 (37) 0.001 1589/5483 (29) 259/696 (37) 0.001 897/2754 (33) 932/3343 (28) 0.001
Antihypertensive 2891/6283 (46) 66/107 (62) 0.001 2715/5922 (46) 247/462 (53) 0.002 2488/5475 (45) 375/693 (54) 0.001 1398/2745 (51) 1431/3342 (43) 0.001
Blood glucose,
mg/dL
116 126 0.005 115 129 0.001 115 125 0.001 121 113 0.001
Weight, kg 75 80 0.03 75 78 0.01 75 75.5 0.9 75 76 0.096
NIHSS score ex
dmf
12 13 0.046 12 15 0.001 12 18 0.001 16 9 0.001
NIHSS score 0–7
ex dmf
1481/6328 (23) 11/107 (10) 0.003 1440/5961 (24) 50/468 (11) 0.001 1381/5511 (25) 37/699 (5) 0.001 225/2772 (8) 1172/3356 (35) 0.001
Systolic blood
pressure, mm Hg
150 160 0.001 150 157 0.001 150 152 0.02 150 150 0.03
Systolic blood
pressure
160 mm Hg
1928/6275 (31) 46/107 (43) 0.003 1787/5909 (30) 186/467 (40) 0.001 1666/5480 (30) 244/697 (35) 0.04 911/2759 (33) 977/3337 (29) 0.006
Diastolic blood
pressure, mm Hg
81 85 0.29 81 82 0.30 81 81 0.79 80 82 0.21
Diastolic blood
pressure
90 mm Hg
1437/6275 (23) 31/107 (29) 0.33 1353/5909 (23) 112/467 (24) 0.56 1239/5480 (23) 178/697 (26) 0.004 632/2759 (23) 769/3337 (23) 0.19
Signs of current
infarction at
baseline imaging
1280/6306 (20) 26/106 (25) 0.22 1173/5940 (20) 126/466 (27) 0.001 1109/5489 (20) 167/696 (24) 0.001 648/2762 (23) 606/3341 (18) 0.001
Time from stroke
onset to treatment,
minutes
140 140 0.59 140 145 0.55 140 145 0.39 140 140 0.32
Alteplase dose,
mg/kg body weight
0.90 0.90 0.07 0.90 0.90 0.16 0.90 0.90 0.0119 0.90 0.90 0.94
Any antiplatelet 393/6300 (6) 11/107 (10) 0.09 370/5937 (6) 36/464 (8) 0.19 330/5487 (6) 70/696 (10) 0.001 202/2755 (7) 195/3346 (6) 0.02
*For continuous variables, the median and P values of the Wilcoxon test are shown. For categorical variables, the number of events divided by the total number
(missing cases excluded); the resulting proportion and the P values of the Pearson 2 test are shown.
dmf indicates distal motor function.
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Results
In SITS-MOST, 6483 patients were included at 285 centers
across 14 European countries between December 2002 and
April 2006. Table 1 shows the baseline and demographic
characteristics of patients according to SICH as per the
SITS-MOST and RCT definitions, mortality, and rate of
independence at 3 months.
The Figure shows the OR and 95% CIs for the variables
appearing in the final model of the backward stepwise
multivariable regression analyses (P0.10). Older age, high
blood glucose, and high NIHSS score at baseline were
significantly related to poor outcome in all parameters. A sign
of current infarction on baseline imaging scans was also
related to poor outcome in all parameters except for SICH per
the SITS-MOST definition. An uncertain current infarction
on the baseline imaging scans was also related to poor
outcome compared with no sign of current infarction for
mortality and independence at 3 months.
Systolic blood pressure and weight were additional predic-
tors of both types of SICH. Aspirin therapy at stroke onset
was related to a high rate of SICH per SITS-MOST definition
and atrial fibrillation was related to a high rate of SICH per
RCT definition. Current smokers had a significantly lower
rate of SICH per RCT definition.
Disability before current stroke (mRS 2 to 5), diastolic
blood pressure 90 mm Hg, antiplatelet other than aspirin,
congestive heart failure, patients treated in new centers, male
sex, and lower alteplase dose in milligrams/kilograms body
weight were related to high mortality at 3 months. Disability
before current stroke (mRS 2 to 5), diastolic blood pressure
90 mm Hg, and previous stroke were related to lower
functional independence at 3 months.
Table 2 shows the unadjusted and adjusted outcomes of
SITS-MOST based on the prediction models. Outcome data
for pooled RCTs were extracted from the 0- to 3-hour pooled
alteplase studies and their unadjusted outcome results and
95% CI were compared.
The adjusted proportion of SICH per RCT definition for
SITS-MOST was 8.5% (95% CI, 7.9 to 9.0) compared with
8.6% (6.3 to 11.6) in the pooled RCTs. The adjusted
proportion of mortality was 15.5% (14.7 to 16.2) versus
17.3% (14.1 to 21.1), and the rate of independence was 50.4%
(49.6 to 51.2) versus 50.1% (44.5 to 54.7), respectively.
SICH according to the SITS-MOST protocol definition
could not be used for comparison with RCTs because these
Figure. OR and 95% CIs based on the first multivariable analysis for those baseline variables appearing in the final model of the back-
ward, stepwise multiple logistic regression analyses. A, SICH per SITS-MOST definition: NIHSS score worsening 4 within 24 hours
plus intracerebral hemorrhage type PH2. B, SICH as per the RCT definition: NIHSS score worsening 1 within 7 days plus any type of
hemorrhage. C, Mortality within 3 months. D, Rate of independence measured by mRS 0 to 2 at 3 months.
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data were not available. The adjusted SICH proportion for
SITS-MOST according to this definition was 2.0% (95% CI,
1.7 to 2.3). The c statistic was 0.736 (0.701 to 0.773).
For SICH as per the RCT definition, the mean (95% CI) for
c statistic was 0.674 (0.635 to 0.712) after crossvalidation.
For mortality at 3 months, the c statistic was 0.752 (0.722 to
0.780) after crossvalidation. For rate of independence at 3
months, the c statistic was 0.782 (0.765 to 0.799) after
crossvalidation.
Discussion
The results of this multivariable analysis reinforce the previ-
ous SITS-MOST report1 that intravenous alteplase is safe and
that the effects were comparable with those seen in RCTs in
a routine clinical setting when administered to suitable
patients within 3 hours of the onset of acute ischemic stroke.
The prediction models used for calculating the adjusted main
outcomes were built on SITS-MOST data and applied to the
RCT patient case-mix. The results showed that the trend
toward favorable outcomes in SITS-MOST compared with
RCTs2 in the unadjusted analysis1 was mainly due to differ-
ences in baseline characteristics between SITS-MOST and
RCTs.
We identified several important predictors for SICH, mor-
tality, and rate of independence in the first multivariable
analyses. Our findings support some of the previously pub-
lished results of prognostic factors for intravenous
thrombolysis in acute ischemic stroke.11–13 Older age, high
blood glucose, and stroke severity as measured by NIHSS
score appeared to be significantly related to poor outcome for
all outcome parameters. The association between NIHSS and
SICH per the SITS-MOST protocol definition was not linear
and, therefore, we categorized the NIHSS score. High systolic
blood pressure but not diastolic blood pressure was related to
both definitions of SICH. Alteplase dose in milligrams/
kilograms body weight was not related to any definition of
SICH but high body weight (in kilograms) was associated
with both SICH definitions. Interestingly, higher dose of
alteplase in milligrams/kilograms body weight was associated
with lower rate of mortality.
Aspirin treatment at stroke onset was related to SICH as
per the SITS-MOST definition but not as per the RCT
definition. These results suggest that concomitant aspirin
treatment at stroke onset in patients receiving thrombolysis
increases the risk for large intracerebral hemorrhage. How-
ever, it should be noted that the overall rate of SICH per
SITS-MOST definition was very low (1.7% unadjusted and
1.9% after adjustment). Patients treated with other antiplatelet
agents (combined variable for dipyridamole, clopidogrel, and
other unspecified) was associated with higher mortality at 3
months, but importantly, this was not due to high rates of
SICH. Antiplatelet treatment for patients with stroke on
thrombolysis is largely unexplored and further research in
this area is needed to establish optimal antiplatelet treatment
strategies.
Current smoking appeared to be related to lower incidence
of SICH as per the RCT definition, a result that has previ-
ously been observed in the National Institute of Neurological
Diseases and Stroke (NINDS) study.14 A secondary analysis
of NINDS data also indicated that recent smokers treated with
intravenous alteplase had a significant drop in NIHSS score at
24 hours and lower mortality over 1 year. In the unadjusted
analysis, there were fewer smokers in the better outcome
group, but this did not remain significant in the multivariable
analysis.15
Stroke severity at baseline measured by NIHSS score and
functional disability before current stroke measured by a
mRS 2 to 5 appeared to be the strongest predictors for
mortality and rate of independence at 3 months. These factors
are already recognized to be strong outcome predictors.16
Signs of current infarction on the pretreatment imaging scans
were related to high mortality and a low rate of independence
at 3 months. A sign of current infarction was also related to
SICH per RCT definition but not to SICH per SITS-MOST
definition. Male sex was associated with increased mortality,
which has also been observed in other studies.11,17,18 Previous
hypertension and high diastolic blood pressure at baseline
were predictors of poor outcome of independence.
As observed in the unadjusted analysis, patients treated in
new centers participating in SITS-MOST had a higher rate of
Table 2. Adjusted Outcome Results From the Second Multivariable Analysis for SITS-MOST Based on the
Multivariable Prediction Models*
Outcome Variables†
SITS-MOST
Pooled RCT
(0 to 3 hours)
Unadjusted Analysis Adjusted as per RCT Case-Mix Unadjusted Analysis
SICH by RCT‡ 7.3 (6.7 to 7.9) 8.5 (7.9 to 9.0) 8.6 (6.3 to 11.6)2
SICH by SITS-MOST§ 1.7 (1.4 to 2.0) 2.0 (1.7 to 2.3) Not available
Mortality within 3 months 11.3 (10.5 to 12.1) 15.5 (14.7 to 16.2) 17.3 (14.1 to 21.1)
Rate of independence at 3 months 54.8 (53.5 to 56.0) 50.4 (49.6 to 51.2) 50.1 (44.5 to 54.7)
*Unadjusted outcomes from SITS-MOST and alteplase arm of the pooled RCTs (0 to 3 hours) are provided for comparison. Values
are proportions with 95% CIs.
†Outcomes were adjusted for variables that were present in both SITS-MOST and pooled alteplase randomized, controlled trial
databases and appearing either in the final model of the multivariable backward stepwise logistic regression analyses or differing
statistically significantly (P0.10) between SITS-MOST and pooled randomized, controlled trial data.
‡Symptomatic (any NIHSS deterioration within 7 days or death) plus any intracerebral hemorrhage as per the RCT definition.
§SICH per SITS-MOST definition: NIHSS score worsening 4 within 24 hours plus intracerebral hemorrhage type PH2.
Measured as mRS of 0 to 2.
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mortality than those treated in experienced centers1 also in the
multivariable model. Importantly, as in the unadjusted anal-
ysis, treatment in new centers was not associated with any
definition of SICH in the multivariable analysis. This result
supports the explanation, as stated in the previous report, that
the higher mortality in new centers compared with experi-
enced centers was not due to alteplase treatment. It is also
supported by a recent analysis of pooled RCT data suggesting
that alteplase treatment does not have any detrimental effect
on mortality rate after stroke.11 The available baseline and
demographic data could not explain the reasons for the
difference in mortality between new and experienced centers.
There are a few limitations to this study. First, the
comparisons made are between data collected in an observa-
tional study and from historical controls, so any conclusion,
even after careful multivariable analysis, should be inter-
preted with caution. Second, we were unable to compare the
SITS-MOST definition of SICH with RCTs, because RCT
SICH outcome data with this definition were not available.
The only available solution was to compare SICH data as per
the RCT definition.2 The RCT definition may include small
hemorrhagic transformations within large infarct edemas, in
which the edema rather than the hemorrhage is the likely
major cause of any clinical deterioration. Adjusted SICH rate
according to the SITS-MOST definition was slightly higher
than in the previous report based on an unadjusted analysis.1
Despite these limitations, SITS-MOST is the largest data-
base in stroke thrombolysis developed so far. The SITS-
MOST protocol, developed in close collaboration with Boeh-
ringer Ingelheim and the EMEA, stated that the primary
analysis should include the unadjusted comparison between
the study data and RCT data, which has been reported
previously.1 The prediction model used in the multivariable
analysis to adjust the SITS-MOST outcome has been vali-
dated internally and well described in the literature.11,12,19 The
prediction model was built on SITS-MOST baseline variables
shown to be prognostically important in the first analysis and
baseline variables not appearing as prognostically important
but differing significantly between SITS-MOST and RCT. It
can be discussed whether the later variables should be
included in the prediction model; however, the results were
practically identical if they were removed. We believe that for
future similar observational studies, the approach used in this
article may provide additional value for comparisons between
monitoring study results and RCTs.
Conclusions
SITS-MOST outcomes adjusted to the RCT case-mix were
almost identical to those in relevant pooled alteplase RCTs.
The trend toward more favorable outcomes in SITS-MOST
compared with RCTs in the unadjusted analysis seemed to be
explained by baseline differences. The results support the
previous conclusion based on an unadjusted analysis,1 that
intravenous alteplase is safe and that the effects were com-
parable with those in RCTs in routine clinical use when
administered within 3 hours to suitable patients with acute
ischemic stroke. We identified several important predictors
for SICH, mortality, and rate of independence in the multi-
variable analyses. These prognostically important variables
and the prediction model, based on SITS-MOST, could be
used to assist patient selection for thrombolysis after acute
ischemic stroke.
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